9,570 reports of this reaction
2.4% of all INSULIN GLARGINE reports
#6 most reported adverse reaction
NAUSEA is the #6 most commonly reported adverse reaction for INSULIN GLARGINE, manufactured by sanofi-aventis U.S. LLC. There are 9,570 FDA adverse event reports linking INSULIN GLARGINE to NAUSEA. This represents approximately 2.4% of all 399,332 adverse event reports for this drug.
Patients taking INSULIN GLARGINE who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is a less commonly reported adverse event for INSULIN GLARGINE, but still significant enough to appear in the safety profile.
In addition to nausea, the following adverse reactions have been reported for INSULIN GLARGINE:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 9,570 FDA reports for INSULIN GLARGINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 2.4% of all adverse event reports for INSULIN GLARGINE, making it a notable side effect.
If you experience nausea while taking INSULIN GLARGINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.